ANBIO BIOTECHNOLOGY Financials
ANBIO BIOTECHNOLOGY (NNNN) reported $8.6M in revenue for fiscal year 2025, up 5.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cost-driven margin expansion lifted FY2025 earnings, but cash conversion reversed as operating and investing demands outpaced reported profit.
FY2025 net income reached$6.4M while operating cash flow was-$6.7M , a wide earnings-to-cash gap rather than a simple profitability story. Accounts receivable also rose from$1.1M in FY2024 to$3.7M in FY2025 despite only modest revenue growth, indicating that reported sales were not converting into cash at the same pace.
Gross margin expansion from
Liability dependence decreased: total liabilities fell from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of ANBIO BIOTECHNOLOGY's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
ANBIO BIOTECHNOLOGY has an operating margin of 66.7%, meaning the company retains $67 of operating profit per $100 of revenue. This strong profitability earns a score of 87/100, reflecting efficient cost management and pricing power. This is up from 24.4% the prior year.
ANBIO BIOTECHNOLOGY's revenue grew 5.6% year-over-year to $8.6M, a solid pace of expansion. This earns a growth score of 72/100.
ANBIO BIOTECHNOLOGY carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 89/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 344.31, ANBIO BIOTECHNOLOGY holds $344.31 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 97/100.
Not available for ANBIO BIOTECHNOLOGY, and counted as zero in the overall score.
ANBIO BIOTECHNOLOGY earns a strong 21.2% return on equity (ROE), meaning it generates $21 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 82/100. This is up from 13.8% the prior year.
ANBIO BIOTECHNOLOGY scores 2302.80, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($336.6M) relative to total liabilities ($88K). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
ANBIO BIOTECHNOLOGY passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, ANBIO BIOTECHNOLOGY used $1.05 of operating cash (-$6.7M OCF vs $6.4M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Key Financial Metrics
Earnings & Revenue
ANBIO BIOTECHNOLOGY generated $8.6M in revenue in fiscal year 2025. This represents an increase of 5.6% from the prior year.
ANBIO BIOTECHNOLOGY reported $6.4M in net income in fiscal year 2025. This represents an increase of 169.9% from the prior year.
ANBIO BIOTECHNOLOGY earned $0.15 per diluted share (EPS) in fiscal year 2025. This represents an increase of 162.5% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
ANBIO BIOTECHNOLOGY held $7.8M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
ANBIO BIOTECHNOLOGY's gross margin was 87.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 15.3 percentage points from the prior year.
ANBIO BIOTECHNOLOGY's operating margin was 66.7% in fiscal year 2025, reflecting core business profitability. This is up 42.3 percentage points from the prior year.
ANBIO BIOTECHNOLOGY's net profit margin was 74.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 45.1 percentage points from the prior year.
ANBIO BIOTECHNOLOGY's ROE was 21.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 7.4 percentage points from the prior year.
Capital Allocation
ANBIO BIOTECHNOLOGY invested $201K in research and development in fiscal year 2025. This represents a decrease of 55.7% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
NNNN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'25 | Q4'24 | Q4'23 |
|---|
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, Interest Expense, Income Tax, Net Income, EPS (Diluted).
NNNN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'25 | Q4'24 | Q4'23 |
|---|---|---|---|
| Total Assets | $30.2M+59.8% | $18.9M+19.7% | $15.8M |
| Current Assets | $30.2M+63.2% | $18.5M+17.7% | $15.7M |
| Cash & Equivalents | $7.8M-34.0% | $11.8M+21.4% | $9.7M |
| Accounts Receivable | $3.7M+243.3% | $1.1M-43.5% | $1.9M |
| Total Liabilities | $88K-94.9% | $1.7M+74.2% | $993K |
| Current Liabilities | $88K-94.9% | $1.7M+74.2% | $993K |
| Total Equity | $30.2M+75.4% | $17.2M+16.0% | $14.8M |
| Retained Earnings | $23.6M+37.3% | $17.2M+16.0% | $14.8M |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
NNNN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'25 | Q4'24 | Q4'23 |
|---|
Not reported in any period shown, so not listed: Operating Cash Flow, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
NNNN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q4'25 | Q4'24 | Q4'23 |
|---|---|---|---|
| Current Ratio | 344.31+333.6x | 10.71-5.1x | 15.86 |
| Debt-to-Equity | 0.00-0.1x | 0.100.0x | 0.07 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, FCF Margin.
Similar Companies
Where ANBIO BIOTECHNOLOGY Ranks
Frequently Asked Questions
What is ANBIO BIOTECHNOLOGY's annual revenue?
ANBIO BIOTECHNOLOGY (NNNN) reported $8.6M in total revenue for fiscal year 2025. This represents a 5.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is ANBIO BIOTECHNOLOGY's revenue growing?
ANBIO BIOTECHNOLOGY (NNNN) revenue grew by 5.6% year-over-year, from $8.2M to $8.6M in fiscal year 2025.
Is ANBIO BIOTECHNOLOGY profitable?
Yes, ANBIO BIOTECHNOLOGY (NNNN) reported a net income of $6.4M in fiscal year 2025, with a net profit margin of 74.1%.
What is ANBIO BIOTECHNOLOGY's gross margin?
ANBIO BIOTECHNOLOGY (NNNN) had a gross margin of 87.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is ANBIO BIOTECHNOLOGY's operating margin?
ANBIO BIOTECHNOLOGY (NNNN) had an operating margin of 66.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is ANBIO BIOTECHNOLOGY's net profit margin?
ANBIO BIOTECHNOLOGY (NNNN) had a net profit margin of 74.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is ANBIO BIOTECHNOLOGY's return on equity (ROE)?
ANBIO BIOTECHNOLOGY (NNNN) has a return on equity of 21.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is ANBIO BIOTECHNOLOGY's operating cash flow?
ANBIO BIOTECHNOLOGY (NNNN) recorded an outflow of $6.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are ANBIO BIOTECHNOLOGY's total assets?
ANBIO BIOTECHNOLOGY (NNNN) had $30.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does ANBIO BIOTECHNOLOGY spend on research and development?
ANBIO BIOTECHNOLOGY (NNNN) invested $201K in research and development during fiscal year 2025.
What is ANBIO BIOTECHNOLOGY's current ratio?
ANBIO BIOTECHNOLOGY (NNNN) had a current ratio of 344.31 as of fiscal year 2025, which is generally considered healthy.
What is ANBIO BIOTECHNOLOGY's debt-to-equity ratio?
ANBIO BIOTECHNOLOGY (NNNN) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is ANBIO BIOTECHNOLOGY's return on assets (ROA)?
ANBIO BIOTECHNOLOGY (NNNN) had a return on assets of 21.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does ANBIO BIOTECHNOLOGY's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, ANBIO BIOTECHNOLOGY (NNNN) held $11.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $6.7M over that year. Dividing the one by the other, the reported balance equals about 21 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is ANBIO BIOTECHNOLOGY's Altman Z-Score?
ANBIO BIOTECHNOLOGY (NNNN) has an Altman Z-Score of 2302.80, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is ANBIO BIOTECHNOLOGY's Piotroski F-Score?
ANBIO BIOTECHNOLOGY (NNNN) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are ANBIO BIOTECHNOLOGY's earnings high quality?
For every $1 of reported earnings, ANBIO BIOTECHNOLOGY (NNNN) used $1.05 of operating cash (-$6.7M OCF vs $6.4M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is ANBIO BIOTECHNOLOGY?
ANBIO BIOTECHNOLOGY (NNNN) scores 71 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.